Abbott’s HIV Drug Patent Plea Rejected for Lack of Novelty Abbott’s HIV Drug Patent Plea Rejected for Lack of Novelty – I-MAK

Abbott’s HIV Drug Patent Plea Rejected for Lack of Novelty

Media Article 4 Jan 2011

The rejection of Abbott’s patent application over a combination of lopinavir and ritonavir, sold under the brand name Aluvia, ended the four-year long intellectual property battle between the company and four pre-grant opponents. Business Standard

Partner with us now to build
a more just and equitable
medicine system for all.